#Ireland #Dublin #Neuromod #Lenire #Joe Ghiz

Neuromod Welcomes New High-Level Appointments

Neuromod Devices, known for its pioneering work in tinnitus treatment, has recently made significant additions to its leadership team. The company announced the hiring of Joe Ghiz as Chief Commercial Officer (CCO) and Shannon Basham as Vice President of Channel Development.

Leadership Overview

Joe Ghiz joins Neuromod with a wealth of experience, having previously held executive positions at Align Technology, the parent company of the widely recognized Invisalign brand, and at Johnson & Johnson. As CCO, Ghiz will spearhead the company’s global commercial strategy, aiming to expand access to Lenire, an innovative bimodal neuromodulation device aimed at alleviating tinnitus.

Shannon Basham brings over two decades of audiology experience to her new role. Her prior position as Senior Audiology Director at Sonova Group has equipped her with unique insights that she will use to direct Neuromod's channel development. Basham's expertise will help strengthen partnerships within the audiological community, essential for the promotion and distribution of Lenire.

Commenting on the New Appointments

Dr. Ross O'Neill, CEO of Neuromod, expressed his enthusiasm about the new hires, stating, “We are at a pivotal moment in our journey. With strong clinical evidence, global regulatory approvals, and a rapidly growing commercial adoption, our company is poised for significant growth. Joe and Shannon’s extensive backgrounds will be invaluable in achieving our mission.”

In particular, Ghiz's previous contributions at Align are noteworthy. He was instrumental in creating a new category of aligners that revolutionized orthodontic practices. His strategic leadership helped drive growth and enhance patient access to orthodontic care, aligning closely with Neuromod’s objectives. With Ghiz at the helm of Neuromod's commercial operations, the company aims to establish Lenire as a new standard of care for tinnitus, targeting ear, nose, and throat specialists and audiologists.

Experience and Vision

In his own words, Ghiz remarked, “I am excited to join Neuromod at such a critical point in the company's development. Lenire has already transformed the lives of numerous tinnitus patients and has the potential to revolutionize treatment practices. I'm eager to work with the Neuromod team to implement strategies that will enhance clinical engagement and broaden patient access to this life-altering technology.”

Basham's extensive background in audiology will further enhance Neuromod's capabilities. Having spent years in leadership roles at Sonova, Basham has a comprehensive understanding of both the market and educational needs of audiologists. She previously led clinical training initiatives that allied product features with effective consumer benefits, thereby supporting corporate sales objectives in her prior role at Sonova. Her deep sector knowledge will ensure that Neuromod's messaging about Lenire resonates with both clinicians and patients alike.

About Neuromod Devices

Neuromod Devices operates globally with offices in Ireland and North America. The company focuses on the design and development of neuromodulation technologies to meet the clinical needs of tinnitus patients. Their device, Lenire, is the first non-invasive bimodal neuromodulation device for tinnitus, integrating auditory stimulation with tongue surface stimulation through the innovative Tonguetip® technology. Prescribed by qualified health professionals, Lenire allows patients to complete treatments at home while benefiting from robust clinical research supporting its efficacy.

With CE certification and FDA De Novo approval in the U.S., Lenire is gaining recognition as a leading treatment option available in multiple countries including the U.S., Canada, Europe, and Australia. Neuromod also partners with the U.S. Department of Veterans Affairs, making Lenire a viable treatment option for veterans dealing with tinnitus.

For more information about Neuromod and Lenire, visit their official website at www.neuromod.com.